Products
Lampalizumab Biosimilar Fab Antibody Fragment (Complement Factor D) for Research
Pre-Made Lampalizumab biosimilar, Fab, Anti-CFD Antibody: Anti-ADIPSIN/ADN/DF/PFD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-293-1mg | 1mg | 3090 |
| GMP-Bios-ab-293-10mg | 10mg | |
| GMP-Bios-ab-293-100mg | 100mg | |
| GMP-Bios-ab-293-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lampalizumab biosimilar, Fab, Anti-CFD Antibody: Anti-ADIPSIN/ADN/DF/PFD therapeutic antibody |
| INN Name | Lampalizumab |
| Target | CFD |
| Format | Fab |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | 4d9q:HL:ED/4d9r:HL:ED |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Tanox;Genentech |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Dry age-related macular degeneration |
| Development Tech | na |
About target - CFD
1. Protein Complement factor D
2. Gene CFD
3. Organism Homo sapiens (Human)
Function
Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. Its function is homologous to that of C1s in the classical pathway.
Catalytic activity
Selective cleavage of Arg-|-Lys bond in complement factor B when in complex with complement subcomponent C3b or with cobra venom factor. EC:3.4.21.46
